title: Safinamide for symptoms of Parkinson's disease.
abstract: Chronic and slow progression of neuronal death in Parkinson's disease is responsible for an altered neurotransmission of various biogenic amines, such as dopamine. Therefore, an individually different pronounced heterogeneity of motor and nonmotor symptoms characterizes each Parkinson's disease patient. Ideal candidates for the balance of these neurotransmitter deficits are compounds like safinamide with broad mechanisms of action such as reversible monoamine oxidase type B inhibition, blockage of voltage-dependent sodium channels, modulation of calcium channels and of glutamate release. Safinamide is administered one time daily with oral doses ranging from 50 to 100 mg. Safinamide was well tolerated and safe, ameliorated motor symptoms when combined with dopamine agonist only or additional levodopa in clinical trials. Safinamide is a novel instrument for the drug therapy of Parkinson's disease with better safety and tolerability particularly concerning diarrhea than inhibitors of catechol-O-methyltransferase, like entacapone, according to an indirect comparison within a meta-analysis with entacapone.
authors.affiliation: Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Berlin, Germany. thomas.mueller@ruhr-uni-bochum.de.
authors.forename: T
authors.initials: T
authors.lastname: Müller
mesh_terms: D000409:Alanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001596:Benzylamines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000494:pharmacology; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D001596:Benzylamines; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; C092797:safinamide; D000409:Alanine
keywords: Dopamine substitution; Glutamate; Glutamate release inhibition; MAO-B inhibition; Parkinson's disease; Safinamide